Abstracts tagged "clinical research and spondylarthritis"

Abstract Number: 2149 • 2015 ACR/ARHP Annual Meeting
Dose Reduction Compared with Standard Dosing for Maintenance of Remission in Patients with Spondyloarthropathies and Clinical Remission with Anti-TNF: A Randomised Real-Life Trial
Jorge Gratacos-Masmitja¹, Caridad Pontes², Ferran Torres³, Xavier Juanola⁴, Antoni Vallano⁵, TC Salman-Monte⁶, Francisco J. Blanco⁷, Agusti Sellas-Fernandez⁸, Raimon Sanmarti⁹, Gonzalo Calvo¹⁰, Teresa Clavaguera¹¹, Raul Veroz Gonzalez¹², Juan Carlos Torre Alonso¹³, Jesus Sanz¹⁴, Cristina Avendaño¹⁵, Carlos Rodriguez-Lozano¹⁶, Luis Francisco Linares¹⁷, Ana Urruticoechea¹⁸, Eduardo Collantes-Estévez¹⁹, Rosa Morla Novell²⁰, Delia Reina²¹, Eduardo Cuende²², Pedro Zarco²³, Cruz Fernández- Espartero²⁴, Rosario Garcia-Vicuña²⁵, Carlos Alberto Montilla Morales²⁶, Eugenio De Miguel²⁷, Roser Vives² and Mireia Moreno²⁸, ¹Rheumatology, Hospital de Sabadell - Institut Universitari Parc Taulí, Sabadell, Spain, ²Clinical Pharmacology, Hospital de Sabadell - Institut Universitari Parc Taulí, Sabadell, Spain, ³Biostatistics and Data Management Platform, IDIBAPS - Hospital Clínic de Barcelona, Barcelona, Spain, ⁴Rheumatology, Hospital Universitari de Bellvitge, Barcelona, Spain, ⁵Hospital de Bellvitge, Barcelona, Spain, ⁶Rheumatology, Hospital del Mar/Parc de Salut Mar, Barcelona, Spain, ⁷Osteoarticular and Aging Research Lab. Proteomics Unit - Associated Node to ProteoRed, Rheumatology Division, Proteomics Group-ProteoRed/ISCIII, INIBIC-CHUAC, A Coruña, Spain, ⁸Rheumatology, Hospital Universitario Valle Hebron, Barcelona, Spain, ⁹Rheumatology Department, Hospital Clinic i Provincial, Barcelona, Spain, ¹⁰Hospital Clínic de Barcelona, Barcelona, Spain, ¹¹CapiCAT group (Nailfold Capillaroscopy group from the Catalan Society for Rheumatology)., Catalonia, Spain, ¹²Hospital de Mérida, Mérida, Spain, ¹³Perez de la Sala 33, 3oA., H. Monte Naranco, Oviedo, Spain, ¹⁴Rheumatology, Hospital Puerta de Hierro Majadahonda, Madrid, Spain, ¹⁵Hospital Puerta de Hierro - Majadahonda, Madrid, Spain, ¹⁶Hospital Ubniversitario Dr. Negrin, Las Palmas de Gran Canaria, Spain, ¹⁷Rheumatology, Hospital Virgen de la Arrixaca, Murcia, Spain, ¹⁸Hospital Can Misses, Ibiza, Spain, ¹⁹IMIBIC-Reina Sofia University Hospital, Rheumatology Unit, Cordoba, Spain, ²⁰Rheumatology UNit., Hospital Sta Tecla, Tarragona, Spain, ²¹Rheumatology, Hospital de Sant Joan Despí Moisès Broggi, Barcelona, Spain, ²²University Hospital Príncipe de Asturias, Immune System Diseases, Rheumatology department, Alcalá de Henares, Madrid, Spain, ²³H Fundación Alcorcón, Alcorcón, Spain, ²⁴Rheumatology, Hospital La Zarzuela, Madrid, Spain, ²⁵Rheumatology, Hospital Universitario de La Princesa. IIS La Princesa, Madrid, Spain, ²⁶Rheumatology, Hospital Universitario de Salamanca, Salamanca, Spain, ²⁷Rheumatology, University Hospital La Paz, Madrid, Spain, ²⁸Hospital de Sabadell - Institut Universitari Parc Taulí, Sabadell, Spain
Background/Purpose: Tumour Necrosis Factor alpha inhibitors (TNFi) have proven to be effective in the treatment of with spondyloarthropaties. There is rationale to support that in…
Abstract Number: 2466 • 2013 ACR/ARHP Annual Meeting
Long Term Efficacy Over Five Years Of Adalimumab In Patients With Active Non – Radiographic Axial Spondyloarthritis
Hildrun Haibel¹, Xenofon Baraliakos², Joachim Listing³, Juergen Braun⁴ and Joachim Sieper¹, ¹Charité Universitätsmedizin Berlin, Berlin, Germany, ²Rheumatology, Rheumazentrum Ruhrgebiet, Herne, Germany, ³German Rheumatism Research Center, Berlin, Germany, ⁴Rheumazentrum Ruhrgebiet, Herne, Germany
Background/Purpose: Adalimumab had demonstrated good efficacy in 46 patients with active non-radiographic axial SpA in a 12-weeks, placebo-controlled trial with a 40-weeks, open-label extension.1,2In 19…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].